Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor

Only 15-20% of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients derive long-term benefit from nivolumab or pembrolizumab. We developed a ctDNA tumor-agnostic assay aimed at the early prediction of single agent PD-1 inhibitor efficacy in R/M SCCHN.

Source: European Journal of Cancer - October 7, 2023 Category: Cancer & Oncology Authors: Natasha Honor é, Athenaïs van der Elst, Anne Dietz, Cédric van Marcke, Raphael Helaers, Antonella Mendola, Hajar Dahou, Etienne Marbaix, Renaud Poncin, Emanuel Seront, Sandra Schmitz, Nisha Limaye, Rachel Galot, Jean-Pascal Machiels Tags: Original Research Source Type: research